Campbell K, Naranjo A, Hibbitts E, Gastier-Foster JM, Bagatell R, Irwin MS, Shimada H, Hogarty M, Park JR, DuBois SG. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children’s Oncology Group. Eur J Cancer. 2020 Jul;133:112-119. doi: 10.1016/j.ejca.2020.04.007. Epub 2020 May 31. PubMed PMID: 32492633; PubMed Central PMCID: PMC7295664.
Study ID Citation
Abstract
MYCN amplification (MNA) is associated with poor outcomes in neuroblastoma. Less is known about heterogeneous MNA within a tumor. We compared clinical characteristics, biologic features, and clinical outcomes of patients with heterogeneous MNA to patients with either homogeneous MNA or MYCN wild-type tumors. In this retrospective cohort study, we categorized patients as having tumors with MYCN wild-type, homogeneous MNA (>20% amplified tumor cells) or heterogeneous MNA (≤20% amplified tumor cells). We used chi-squared or Fisher’s exact tests to compare features between groups. We used log-rank tests and Cox models to compare event-free survival (EFS) and overall survival (OS) between groups.